{"title":"siRNA","description":"","products":[{"product_id":"human-eomes-pre-designed-sirna-bhn20105012","title":"Human EOMES Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEOMES\u003c\/strong\u003e gene (NCBI Gene ID: 8320) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005012A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005012B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEOMES\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEOMES\u003c\/strong\u003e gene (Gene ID: 8320) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEOMES\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEOMES\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEOMES\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEOMES\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEOMES\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EOMES in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EOMES siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EOMES expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005012A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EOMES siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EOMES siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EOMES siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005012B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EOMES siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EOMES siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EOMES siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EOMES siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/8320\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165427655021,"sku":"SI005012A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165511016813,"sku":"SI005012B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_82d0b13f-9802-4f55-819c-73ba27cd741d.png?v=1774683681"},{"product_id":"human-eny2-pre-designed-sirna-bhn20105008","title":"Human ENY2 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eENY2\u003c\/strong\u003e gene (NCBI Gene ID: 56943) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005008A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005008B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eENY2\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eENY2\u003c\/strong\u003e gene (Gene ID: 56943) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eENY2\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eENY2\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eENY2\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eENY2\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eENY2\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of ENY2 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent ENY2 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline ENY2 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005008A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ENY2 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENY2 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENY2 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005008B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ENY2 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENY2 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENY2 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENY2 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/56943\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165427687789,"sku":"SI005008A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165511934317,"sku":"SI005008B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_8715d02d-226a-4df9-9e09-41ba303b293e.png?v=1774683685"},{"product_id":"human-entrep2-pre-designed-sirna-bhn20105006","title":"Human ENTREP2 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eENTREP2\u003c\/strong\u003e gene (NCBI Gene ID: 23359) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005006A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005006B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eENTREP2\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eENTREP2\u003c\/strong\u003e gene (Gene ID: 23359) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eENTREP2\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eENTREP2\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eENTREP2\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eENTREP2\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eENTREP2\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of ENTREP2 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent ENTREP2 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline ENTREP2 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005006A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ENTREP2 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTREP2 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTREP2 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005006B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ENTREP2 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTREP2 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTREP2 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTREP2 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/23359\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165427720557,"sku":"SI005006A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165511901549,"sku":"SI005006B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_091cf82e-4ffe-4d29-93d1-32e888101b2e.png?v=1774683679"},{"product_id":"human-entpd6-pre-designed-sirna-bhn20105001","title":"Human ENTPD6 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eENTPD6\u003c\/strong\u003e gene (NCBI Gene ID: 955) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005001A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005001B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eENTPD6\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eENTPD6\u003c\/strong\u003e gene (Gene ID: 955) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eENTPD6\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eENTPD6\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eENTPD6\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eENTPD6\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eENTPD6\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of ENTPD6 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent ENTPD6 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline ENTPD6 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005001A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ENTPD6 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTPD6 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTPD6 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005001B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ENTPD6 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTPD6 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTPD6 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTPD6 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/955\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165427753325,"sku":"SI005001A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165512360301,"sku":"SI005001B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_29d73dbd-7ef6-4425-b08e-78009fcf7242.png?v=1774683677"},{"product_id":"human-ep300-pre-designed-sirna-bhn20105013","title":"Human EP300 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEP300\u003c\/strong\u003e gene (NCBI Gene ID: 2033) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005013A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005013B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEP300\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEP300\u003c\/strong\u003e gene (Gene ID: 2033) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEP300\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEP300\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEP300\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEP300\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEP300\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EP300 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EP300 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EP300 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005013A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EP300 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EP300 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EP300 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005013B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EP300 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EP300 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EP300 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EP300 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/2033\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165427786093,"sku":"SI005013A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165512163693,"sku":"SI005013B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_fc006a18-7afc-4946-a816-bdc4d8f3eefc.png?v=1774683690"},{"product_id":"human-entrep3-pre-designed-sirna-bhn20105007","title":"Human ENTREP3 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eENTREP3\u003c\/strong\u003e gene (NCBI Gene ID: 10712) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005007A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005007B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eENTREP3\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eENTREP3\u003c\/strong\u003e gene (Gene ID: 10712) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eENTREP3\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eENTREP3\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eENTREP3\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eENTREP3\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eENTREP3\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of ENTREP3 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent ENTREP3 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline ENTREP3 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005007A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ENTREP3 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTREP3 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTREP3 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005007B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ENTREP3 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTREP3 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTREP3 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTREP3 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/10712\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165427818861,"sku":"SI005007A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165510164845,"sku":"SI005007B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_a48b95b9-7ab0-4b9e-a276-414150f193ba.png?v=1774683683"},{"product_id":"human-eprs1-pre-designed-sirna-bhn20105060","title":"Human EPRS1 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPRS1\u003c\/strong\u003e gene (NCBI Gene ID: 2058) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005060A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005060B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPRS1\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPRS1\u003c\/strong\u003e gene (Gene ID: 2058) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPRS1\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPRS1\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPRS1\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPRS1\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPRS1\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPRS1 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPRS1 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPRS1 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005060A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPRS1 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPRS1 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPRS1 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005060B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPRS1 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPRS1 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPRS1 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPRS1 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/2058\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165427851629,"sku":"SI005060A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165512589677,"sku":"SI005060B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_611a0c42-ad01-4ab3-abcc-01089a9b4a6b.png?v=1774683688"},{"product_id":"human-epc2-pre-designed-sirna-bhn20105025","title":"Human EPC2 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPC2\u003c\/strong\u003e gene (NCBI Gene ID: 26122) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005025A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005025B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPC2\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPC2\u003c\/strong\u003e gene (Gene ID: 26122) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPC2\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPC2\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPC2\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPC2\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPC2\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPC2 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPC2 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPC2 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005025A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPC2 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPC2 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPC2 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005025B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPC2 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPC2 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPC2 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPC2 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/26122\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165427917165,"sku":"SI005025A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165512622445,"sku":"SI005025B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_12574a29-68ca-4752-acab-01388246291b.png?v=1774683685"},{"product_id":"human-eogt-pre-designed-sirna-bhn20105009","title":"Human EOGT Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEOGT\u003c\/strong\u003e gene (NCBI Gene ID: 285203) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005009A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005009B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEOGT\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEOGT\u003c\/strong\u003e gene (Gene ID: 285203) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEOGT\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEOGT\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEOGT\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEOGT\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEOGT\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EOGT in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EOGT siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EOGT expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005009A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EOGT siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EOGT siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EOGT siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005009B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EOGT siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EOGT siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EOGT siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EOGT siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/285203\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165427884397,"sku":"SI005009A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165513769325,"sku":"SI005009B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_6e1abb01-a0cc-443e-8ee7-1a14cd287cdd.png?v=1774683681"},{"product_id":"human-entrep1-pre-designed-sirna-bhn20105005","title":"Human ENTREP1 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eENTREP1\u003c\/strong\u003e gene (NCBI Gene ID: 9413) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005005A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005005B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eENTREP1\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eENTREP1\u003c\/strong\u003e gene (Gene ID: 9413) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eENTREP1\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eENTREP1\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eENTREP1\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eENTREP1\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eENTREP1\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of ENTREP1 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent ENTREP1 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline ENTREP1 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005005A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ENTREP1 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTREP1 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTREP1 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005005B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ENTREP1 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTREP1 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTREP1 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTREP1 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/9413\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165427949933,"sku":"SI005005A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165512687981,"sku":"SI005005B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_b005f9e1-5481-4898-af33-2c9822149efd.png?v=1774683685"},{"product_id":"human-epcip-pre-designed-sirna-bhn20105027","title":"Human EPCIP Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPCIP\u003c\/strong\u003e gene (NCBI Gene ID: 56245) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005027A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005027B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPCIP\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPCIP\u003c\/strong\u003e gene (Gene ID: 56245) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPCIP\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPCIP\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPCIP\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPCIP\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPCIP\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPCIP in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPCIP siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPCIP expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005027A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPCIP siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPCIP siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPCIP siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005027B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPCIP siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPCIP siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPCIP siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPCIP siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/56245\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165427982701,"sku":"SI005027A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165510132077,"sku":"SI005027B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_b2a11d6a-800f-4d4b-a354-d2195ac56670.png?v=1774683687"},{"product_id":"human-epb41-pre-designed-sirna-bhn20105016","title":"Human EPB41 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPB41\u003c\/strong\u003e gene (NCBI Gene ID: 2035) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005016A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005016B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPB41\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPB41\u003c\/strong\u003e gene (Gene ID: 2035) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPB41\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPB41\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPB41\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPB41\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPB41\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPB41 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPB41 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPB41 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005016A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPB41 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPB41 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPB41 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005016B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPB41 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPB41 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPB41 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPB41 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/2035\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428015469,"sku":"SI005016A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165513474413,"sku":"SI005016B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_d376590a-f95f-4611-b724-6db0bcf68fbc.png?v=1774683687"},{"product_id":"human-ervfrd-2-pre-designed-sirna-bhn20105128","title":"Human ERVFRD-2 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eERVFRD-2\u003c\/strong\u003e gene (NCBI Gene ID: 107985332) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005128A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005128B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eERVFRD-2\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eERVFRD-2\u003c\/strong\u003e gene (Gene ID: 107985332) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eERVFRD-2\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eERVFRD-2\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eERVFRD-2\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eERVFRD-2\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eERVFRD-2\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of ERVFRD-2 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent ERVFRD-2 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline ERVFRD-2 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005128A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ERVFRD-2 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERVFRD-2 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERVFRD-2 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005128B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ERVFRD-2 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERVFRD-2 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERVFRD-2 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERVFRD-2 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/107985332\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428081005,"sku":"SI005128A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165510558061,"sku":"SI005128B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_f1c3a4a8-2027-4d54-8e87-2f7b13b0e80c.png?v=1774683684"},{"product_id":"human-eola1-pre-designed-sirna-bhn20105010","title":"Human EOLA1 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEOLA1\u003c\/strong\u003e gene (NCBI Gene ID: 91966) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005010A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005010B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEOLA1\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEOLA1\u003c\/strong\u003e gene (Gene ID: 91966) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEOLA1\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEOLA1\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEOLA1\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEOLA1\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEOLA1\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EOLA1 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EOLA1 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EOLA1 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005010A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EOLA1 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EOLA1 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EOLA1 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005010B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EOLA1 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EOLA1 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EOLA1 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EOLA1 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/91966\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428048237,"sku":"SI005010A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165513343341,"sku":"SI005010B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_01e17bf8-3a80-4248-8866-358dd1742ec7.png?v=1774683682"},{"product_id":"human-epc1-pre-designed-sirna-bhn20105024","title":"Human EPC1 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPC1\u003c\/strong\u003e gene (NCBI Gene ID: 80314) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005024A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005024B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPC1\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPC1\u003c\/strong\u003e gene (Gene ID: 80314) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPC1\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPC1\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPC1\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPC1\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPC1\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPC1 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPC1 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPC1 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005024A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPC1 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPC1 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPC1 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005024B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPC1 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPC1 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPC1 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPC1 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/80314\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428113773,"sku":"SI005024A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165512982893,"sku":"SI005024B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_f7bfac53-dd27-4906-8a74-d945d6df8177.png?v=1774683682"},{"product_id":"human-epdr1-pre-designed-sirna-bhn20105028","title":"Human EPDR1 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPDR1\u003c\/strong\u003e gene (NCBI Gene ID: 54749) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005028A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005028B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPDR1\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPDR1\u003c\/strong\u003e gene (Gene ID: 54749) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPDR1\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPDR1\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPDR1\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPDR1\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPDR1\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPDR1 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPDR1 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPDR1 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005028A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPDR1 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPDR1 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPDR1 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005028B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPDR1 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPDR1 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPDR1 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPDR1 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/54749\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428146541,"sku":"SI005028A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165511213421,"sku":"SI005028B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_e0b49036-1355-475d-ac29-2adfc2587dd5.png?v=1774683681"},{"product_id":"human-ephb6-pre-designed-sirna-bhn20105044","title":"Human EPHB6 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPHB6\u003c\/strong\u003e gene (NCBI Gene ID: 2051) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005044A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005044B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPHB6\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPHB6\u003c\/strong\u003e gene (Gene ID: 2051) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPHB6\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPHB6\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPHB6\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPHB6\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPHB6\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPHB6 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPHB6 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPHB6 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005044A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPHB6 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHB6 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHB6 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005044B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPHB6 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHB6 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHB6 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHB6 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/2051\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428179309,"sku":"SI005044A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165513703789,"sku":"SI005044B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_008b5ef5-9d69-41b3-9df2-64ba6772ea94.png?v=1774683683"},{"product_id":"human-epha7-pre-designed-sirna-bhn20105038","title":"Human EPHA7 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPHA7\u003c\/strong\u003e gene (NCBI Gene ID: 2045) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005038A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005038B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPHA7\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPHA7\u003c\/strong\u003e gene (Gene ID: 2045) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPHA7\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPHA7\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPHA7\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPHA7\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPHA7\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPHA7 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPHA7 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPHA7 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005038A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPHA7 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHA7 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHA7 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005038B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPHA7 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHA7 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHA7 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHA7 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/2045\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428212077,"sku":"SI005038A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165511115117,"sku":"SI005038B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_7d76b8d6-8714-46d3-a509-bfd0788066d2.png?v=1774683685"},{"product_id":"human-erich5-pre-designed-sirna-bhn20105107","title":"Human ERICH5 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eERICH5\u003c\/strong\u003e gene (NCBI Gene ID: 203111) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005107A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005107B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eERICH5\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eERICH5\u003c\/strong\u003e gene (Gene ID: 203111) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eERICH5\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eERICH5\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eERICH5\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eERICH5\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eERICH5\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of ERICH5 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent ERICH5 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline ERICH5 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005107A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ERICH5 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERICH5 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERICH5 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005107B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ERICH5 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERICH5 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERICH5 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERICH5 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/203111\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428244845,"sku":"SI005107A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165511147885,"sku":"SI005107B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_87dd0077-c283-4e77-b805-eb3d3ee694af.png?v=1774683686"},{"product_id":"human-entpd8-pre-designed-sirna-bhn20105003","title":"Human ENTPD8 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eENTPD8\u003c\/strong\u003e gene (NCBI Gene ID: 377841) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005003A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005003B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eENTPD8\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eENTPD8\u003c\/strong\u003e gene (Gene ID: 377841) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eENTPD8\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eENTPD8\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eENTPD8\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eENTPD8\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eENTPD8\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of ENTPD8 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent ENTPD8 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline ENTPD8 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005003A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ENTPD8 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTPD8 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTPD8 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005003B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ENTPD8 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTPD8 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTPD8 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTPD8 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/377841\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428277613,"sku":"SI005003A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165513867629,"sku":"SI005003B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_fbe33253-c313-4ae6-84a9-2a99edfaa95a.png?v=1774683681"},{"product_id":"human-erg28-pre-designed-sirna-bhn20105095","title":"Human ERG28 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eERG28\u003c\/strong\u003e gene (NCBI Gene ID: 11161) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005095A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005095B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eERG28\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eERG28\u003c\/strong\u003e gene (Gene ID: 11161) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eERG28\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eERG28\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eERG28\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eERG28\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eERG28\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of ERG28 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent ERG28 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline ERG28 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005095A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ERG28 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERG28 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERG28 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005095B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ERG28 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERG28 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERG28 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERG28 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/11161\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428310381,"sku":"SI005095A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165510623597,"sku":"SI005095B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_5ef47fe4-66fe-4439-94ba-f1bd1d3c731e.png?v=1774683687"},{"product_id":"human-epm2a-pre-designed-sirna-bhn20105049","title":"Human EPM2A Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPM2A\u003c\/strong\u003e gene (NCBI Gene ID: 7957) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005049A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005049B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPM2A\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPM2A\u003c\/strong\u003e gene (Gene ID: 7957) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPM2A\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPM2A\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPM2A\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPM2A\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPM2A\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPM2A in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPM2A siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPM2A expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005049A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPM2A siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPM2A siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPM2A siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005049B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPM2A siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPM2A siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPM2A siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPM2A siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/7957\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428343149,"sku":"SI005049A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165511246189,"sku":"SI005049B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_319b812a-b756-40f6-935f-de541f20f11d.png?v=1774683682"},{"product_id":"human-erap2-pre-designed-sirna-bhn20105073","title":"Human ERAP2 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eERAP2\u003c\/strong\u003e gene (NCBI Gene ID: 64167) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005073A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005073B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eERAP2\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eERAP2\u003c\/strong\u003e gene (Gene ID: 64167) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eERAP2\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eERAP2\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eERAP2\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eERAP2\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eERAP2\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of ERAP2 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent ERAP2 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline ERAP2 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005073A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ERAP2 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERAP2 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERAP2 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005073B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ERAP2 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERAP2 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERAP2 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERAP2 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/64167\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428375917,"sku":"SI005073A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165510295917,"sku":"SI005073B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_dd047766-e84c-448e-af9e-7945afe8cd5e.png?v=1774683678"},{"product_id":"human-epha4-pre-designed-sirna-bhn20105035","title":"Human EPHA4 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPHA4\u003c\/strong\u003e gene (NCBI Gene ID: 2043) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005035A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005035B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPHA4\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPHA4\u003c\/strong\u003e gene (Gene ID: 2043) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPHA4\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPHA4\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPHA4\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPHA4\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPHA4\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPHA4 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPHA4 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPHA4 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005035A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPHA4 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHA4 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHA4 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005035B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPHA4 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHA4 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHA4 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHA4 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/2043\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428474221,"sku":"SI005035A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165511278957,"sku":"SI005035B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_fbeede6f-f04b-4b3b-9b93-57e748a2bd91.png?v=1774683684"},{"product_id":"human-eps8-pre-designed-sirna-bhn20105063","title":"Human EPS8 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPS8\u003c\/strong\u003e gene (NCBI Gene ID: 2059) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005063A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005063B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPS8\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPS8\u003c\/strong\u003e gene (Gene ID: 2059) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPS8\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPS8\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPS8\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPS8\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPS8\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPS8 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPS8 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPS8 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005063A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPS8 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPS8 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPS8 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005063B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPS8 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPS8 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPS8 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPS8 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/2059\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428408685,"sku":"SI005063A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165510263149,"sku":"SI005063B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_cbccd6bf-e93e-4b02-b456-e4d526152b0f.png?v=1774683681"},{"product_id":"human-esam-pre-designed-sirna-bhn20105137","title":"Human ESAM Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eESAM\u003c\/strong\u003e gene (NCBI Gene ID: 90952) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005137A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005137B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eESAM\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eESAM\u003c\/strong\u003e gene (Gene ID: 90952) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eESAM\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eESAM\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eESAM\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eESAM\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eESAM\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of ESAM in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent ESAM siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline ESAM expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005137A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ESAM siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ESAM siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ESAM siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005137B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ESAM siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ESAM siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ESAM siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ESAM siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/90952\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428441453,"sku":"SI005137A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165511672173,"sku":"SI005137B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_6b7522eb-749f-4c6f-a0ac-8c461731bd89.png?v=1774683678"},{"product_id":"human-epha2-pre-designed-sirna-bhn20105033","title":"Human EPHA2 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPHA2\u003c\/strong\u003e gene (NCBI Gene ID: 1969) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005033A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005033B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPHA2\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPHA2\u003c\/strong\u003e gene (Gene ID: 1969) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPHA2\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPHA2\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPHA2\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPHA2\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPHA2\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPHA2 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPHA2 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPHA2 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005033A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPHA2 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHA2 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHA2 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005033B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPHA2 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHA2 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHA2 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHA2 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/1969\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428506989,"sku":"SI005033A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165512556909,"sku":"SI005033B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_3f36cef2-00ab-4fa6-8e61-bbbef189daa2.png?v=1774683686"},{"product_id":"human-ephb2-pre-designed-sirna-bhn20105041","title":"Human EPHB2 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPHB2\u003c\/strong\u003e gene (NCBI Gene ID: 2048) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005041A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005041B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPHB2\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPHB2\u003c\/strong\u003e gene (Gene ID: 2048) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPHB2\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPHB2\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPHB2\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPHB2\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPHB2\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPHB2 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPHB2 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPHB2 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005041A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPHB2 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHB2 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHB2 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005041B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPHB2 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHB2 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHB2 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHB2 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/2048\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428539757,"sku":"SI005041A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165512819053,"sku":"SI005041B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_0e183fbe-0c87-465f-9f1f-8bd692fd284d.png?v=1774683685"},{"product_id":"human-epb41l5-pre-designed-sirna-bhn20105022","title":"Human EPB41L5 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPB41L5\u003c\/strong\u003e gene (NCBI Gene ID: 57669) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005022A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005022B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPB41L5\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPB41L5\u003c\/strong\u003e gene (Gene ID: 57669) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPB41L5\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPB41L5\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPB41L5\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPB41L5\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPB41L5\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPB41L5 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPB41L5 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPB41L5 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005022A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPB41L5 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPB41L5 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPB41L5 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005022B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPB41L5 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPB41L5 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPB41L5 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPB41L5 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/57669\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428572525,"sku":"SI005022A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165511377261,"sku":"SI005022B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_f82ae3a2-fa81-4ce1-ae76-f29a62b5af4c.png?v=1774683687"},{"product_id":"human-ervk-19-pre-designed-sirna-bhn20105130","title":"Human ERVK-19 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eERVK-19\u003c\/strong\u003e gene (NCBI Gene ID: 105376906) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005130A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005130B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eERVK-19\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eERVK-19\u003c\/strong\u003e gene (Gene ID: 105376906) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eERVK-19\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eERVK-19\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eERVK-19\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eERVK-19\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eERVK-19\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of ERVK-19 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent ERVK-19 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline ERVK-19 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005130A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ERVK-19 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERVK-19 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERVK-19 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005130B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ERVK-19 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERVK-19 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERVK-19 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERVK-19 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/105376906\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428605293,"sku":"SI005130A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165513802093,"sku":"SI005130B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_9750d2ab-21f1-4e57-b04d-50e87affee7e.png?v=1774683683"},{"product_id":"human-erh-pre-designed-sirna-bhn20105099","title":"Human ERH Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eERH\u003c\/strong\u003e gene (NCBI Gene ID: 2079) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005099A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005099B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eERH\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eERH\u003c\/strong\u003e gene (Gene ID: 2079) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eERH\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eERH\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eERH\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eERH\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eERH\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of ERH in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent ERH siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline ERH expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005099A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ERH siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERH siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERH siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005099B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ERH siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERH siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERH siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERH siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/2079\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428638061,"sku":"SI005099A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165510099309,"sku":"SI005099B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_d25f6bd0-dfce-491c-8bcb-08d057ddd073.png?v=1774683687"},{"product_id":"human-ermard-pre-designed-sirna-bhn20105114","title":"Human ERMARD Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eERMARD\u003c\/strong\u003e gene (NCBI Gene ID: 55780) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005114A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005114B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eERMARD\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eERMARD\u003c\/strong\u003e gene (Gene ID: 55780) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eERMARD\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eERMARD\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eERMARD\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eERMARD\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eERMARD\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of ERMARD in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent ERMARD siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline ERMARD expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005114A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ERMARD siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERMARD siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERMARD siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005114B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ERMARD siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERMARD siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERMARD siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERMARD siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/55780\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428670829,"sku":"SI005114A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165514064237,"sku":"SI005114B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_5e76210a-051d-42d4-9caf-9c85832e501f.png?v=1774683690"},{"product_id":"human-eps15l1-pre-designed-sirna-bhn20105062","title":"Human EPS15L1 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPS15L1\u003c\/strong\u003e gene (NCBI Gene ID: 58513) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005062A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005062B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPS15L1\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPS15L1\u003c\/strong\u003e gene (Gene ID: 58513) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPS15L1\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPS15L1\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPS15L1\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPS15L1\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPS15L1\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPS15L1 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPS15L1 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPS15L1 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005062A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPS15L1 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPS15L1 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPS15L1 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005062B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPS15L1 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPS15L1 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPS15L1 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPS15L1 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/58513\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428703597,"sku":"SI005062A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165511737709,"sku":"SI005062B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_62ceb7f8-44c6-4d31-98b0-adba0f74f243.png?v=1774683681"},{"product_id":"human-ercc3-pre-designed-sirna-bhn20105083","title":"Human ERCC3 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eERCC3\u003c\/strong\u003e gene (NCBI Gene ID: 2071) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005083A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005083B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eERCC3\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eERCC3\u003c\/strong\u003e gene (Gene ID: 2071) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eERCC3\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eERCC3\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eERCC3\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eERCC3\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eERCC3\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of ERCC3 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent ERCC3 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline ERCC3 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005083A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ERCC3 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERCC3 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERCC3 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005083B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ERCC3 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERCC3 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERCC3 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERCC3 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/2071\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428736365,"sku":"SI005083A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165510820205,"sku":"SI005083B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_9b505638-69d2-4e9d-9d8d-b9fb3573f765.png?v=1774683680"},{"product_id":"human-ephx2-pre-designed-sirna-bhn20105046","title":"Human EPHX2 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPHX2\u003c\/strong\u003e gene (NCBI Gene ID: 2053) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005046A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005046B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPHX2\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPHX2\u003c\/strong\u003e gene (Gene ID: 2053) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPHX2\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPHX2\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPHX2\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPHX2\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPHX2\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPHX2 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPHX2 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPHX2 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005046A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPHX2 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHX2 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHX2 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005046B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPHX2 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHX2 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHX2 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHX2 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/2053\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428769133,"sku":"SI005046A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165514260845,"sku":"SI005046B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_2d3998f6-7146-48e9-b2b7-5749bfae64b9.png?v=1774683681"},{"product_id":"human-epha6-pre-designed-sirna-bhn20105037","title":"Human EPHA6 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPHA6\u003c\/strong\u003e gene (NCBI Gene ID: 285220) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005037A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005037B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPHA6\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPHA6\u003c\/strong\u003e gene (Gene ID: 285220) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPHA6\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPHA6\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPHA6\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPHA6\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPHA6\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPHA6 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPHA6 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPHA6 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005037A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPHA6 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHA6 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHA6 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005037B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPHA6 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHA6 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHA6 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHA6 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/285220\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428801901,"sku":"SI005037A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165514850669,"sku":"SI005037B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_5f54970f-25e6-4ff9-a1f5-3cfea5bf9d47.png?v=1774683685"},{"product_id":"human-epb41l4b-pre-designed-sirna-bhn20105021","title":"Human EPB41L4B Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPB41L4B\u003c\/strong\u003e gene (NCBI Gene ID: 54566) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005021A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005021B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPB41L4B\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPB41L4B\u003c\/strong\u003e gene (Gene ID: 54566) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPB41L4B\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPB41L4B\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPB41L4B\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPB41L4B\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPB41L4B\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPB41L4B in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPB41L4B siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPB41L4B expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005021A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPB41L4B siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPB41L4B siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPB41L4B siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005021B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPB41L4B siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPB41L4B siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPB41L4B siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPB41L4B siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/54566\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428834669,"sku":"SI005021A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165514228077,"sku":"SI005021B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_06078c6c-7b50-4228-9849-0baadec864da.png?v=1774683688"},{"product_id":"human-epb41l3-pre-designed-sirna-bhn20105019","title":"Human EPB41L3 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPB41L3\u003c\/strong\u003e gene (NCBI Gene ID: 23136) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005019A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005019B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPB41L3\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPB41L3\u003c\/strong\u003e gene (Gene ID: 23136) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPB41L3\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPB41L3\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPB41L3\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPB41L3\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPB41L3\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPB41L3 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPB41L3 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPB41L3 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005019A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPB41L3 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPB41L3 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPB41L3 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005019B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPB41L3 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPB41L3 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPB41L3 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPB41L3 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/23136\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428867437,"sku":"SI005019A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165513736557,"sku":"SI005019B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_26ee14d6-a9eb-4167-9ef5-c86de9c55e06.png?v=1774683680"},{"product_id":"human-ervv-2-pre-designed-sirna-bhn20105135","title":"Human ERVV-2 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eERVV-2\u003c\/strong\u003e gene (NCBI Gene ID: 100271846) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005135A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005135B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eERVV-2\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eERVV-2\u003c\/strong\u003e gene (Gene ID: 100271846) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eERVV-2\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eERVV-2\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eERVV-2\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eERVV-2\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eERVV-2\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of ERVV-2 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent ERVV-2 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline ERVV-2 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005135A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ERVV-2 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERVV-2 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERVV-2 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005135B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ERVV-2 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERVV-2 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERVV-2 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERVV-2 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/100271846\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428900205,"sku":"SI005135A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165512196461,"sku":"SI005135B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_043b03db-5da9-45af-8bf7-c54d3d5dc4c2.png?v=1774683689"},{"product_id":"human-eps15-pre-designed-sirna-bhn20105061","title":"Human EPS15 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPS15\u003c\/strong\u003e gene (NCBI Gene ID: 2060) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005061A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005061B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPS15\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPS15\u003c\/strong\u003e gene (Gene ID: 2060) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPS15\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPS15\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPS15\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPS15\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPS15\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPS15 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPS15 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPS15 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005061A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPS15 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPS15 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPS15 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005061B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPS15 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPS15 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPS15 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPS15 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/2060\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428932973,"sku":"SI005061A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165511311725,"sku":"SI005061B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_efe7a322-7ce8-4b6a-9ff4-facbfbb9f53d.png?v=1774683683"},{"product_id":"human-ephb3-pre-designed-sirna-bhn20105042","title":"Human EPHB3 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPHB3\u003c\/strong\u003e gene (NCBI Gene ID: 2049) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005042A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005042B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPHB3\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPHB3\u003c\/strong\u003e gene (Gene ID: 2049) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPHB3\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPHB3\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPHB3\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPHB3\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPHB3\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPHB3 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPHB3 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPHB3 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005042A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPHB3 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHB3 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHB3 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005042B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPHB3 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHB3 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHB3 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPHB3 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/2049\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428965741,"sku":"SI005042A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165513376109,"sku":"SI005042B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_e090270a-dc2d-489e-bded-3b5cd3b09c77.png?v=1774683684"},{"product_id":"human-entpd7-pre-designed-sirna-bhn20105002","title":"Human ENTPD7 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eENTPD7\u003c\/strong\u003e gene (NCBI Gene ID: 57089) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005002A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005002B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eENTPD7\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eENTPD7\u003c\/strong\u003e gene (Gene ID: 57089) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eENTPD7\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eENTPD7\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eENTPD7\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eENTPD7\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eENTPD7\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of ENTPD7 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent ENTPD7 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline ENTPD7 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005002A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ENTPD7 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTPD7 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTPD7 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005002B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ENTPD7 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTPD7 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTPD7 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ENTPD7 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/57089\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165428998509,"sku":"SI005002A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165513113965,"sku":"SI005002B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_21fbbb31-db46-40e0-9bff-7b5acdd3e7d7.png?v=1774683686"},{"product_id":"human-eps8l3-pre-designed-sirna-bhn20105066","title":"Human EPS8L3 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPS8L3\u003c\/strong\u003e gene (NCBI Gene ID: 79574) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005066A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005066B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPS8L3\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPS8L3\u003c\/strong\u003e gene (Gene ID: 79574) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPS8L3\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPS8L3\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPS8L3\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPS8L3\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPS8L3\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPS8L3 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPS8L3 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPS8L3 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005066A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPS8L3 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPS8L3 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPS8L3 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005066B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPS8L3 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPS8L3 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPS8L3 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPS8L3 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/79574\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165429031277,"sku":"SI005066A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165513933165,"sku":"SI005066B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_7e4dde62-8707-42fd-b3f2-fd672adb997c.png?v=1774683682"},{"product_id":"human-erlin2-pre-designed-sirna-bhn20105112","title":"Human ERLIN2 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eERLIN2\u003c\/strong\u003e gene (NCBI Gene ID: 11160) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005112A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005112B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eERLIN2\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eERLIN2\u003c\/strong\u003e gene (Gene ID: 11160) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eERLIN2\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eERLIN2\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eERLIN2\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eERLIN2\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eERLIN2\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of ERLIN2 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent ERLIN2 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline ERLIN2 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005112A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ERLIN2 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERLIN2 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERLIN2 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005112B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ERLIN2 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERLIN2 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERLIN2 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERLIN2 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/11160\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165429064045,"sku":"SI005112A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165510328685,"sku":"SI005112B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_f87b0494-424e-4c1a-869b-6abd7fcdb3b4.png?v=1774683680"},{"product_id":"human-epop-pre-designed-sirna-bhn20105055","title":"Human EPOP Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPOP\u003c\/strong\u003e gene (NCBI Gene ID: 100170841) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005055A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005055B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPOP\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPOP\u003c\/strong\u003e gene (Gene ID: 100170841) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPOP\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPOP\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPOP\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPOP\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPOP\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPOP in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPOP siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPOP expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005055A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPOP siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPOP siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPOP siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005055B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPOP siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPOP siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPOP siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPOP siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/100170841\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165429096813,"sku":"SI005055A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165514719597,"sku":"SI005055B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_0b1a8d76-27ac-4eed-ae7c-14f63ceec9cb.png?v=1774683685"},{"product_id":"human-epg5-pre-designed-sirna-bhn20105029","title":"Human EPG5 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPG5\u003c\/strong\u003e gene (NCBI Gene ID: 57724) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005029A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005029B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPG5\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPG5\u003c\/strong\u003e gene (Gene ID: 57724) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPG5\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPG5\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPG5\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPG5\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPG5\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPG5 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPG5 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPG5 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005029A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPG5 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPG5 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPG5 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005029B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPG5 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPG5 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPG5 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPG5 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/57724\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165429129581,"sku":"SI005029A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165514555757,"sku":"SI005029B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_17393de7-a968-4381-9137-9ce0d6e89065.png?v=1774683685"},{"product_id":"human-epyc-pre-designed-sirna-bhn20105069","title":"Human EPYC Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPYC\u003c\/strong\u003e gene (NCBI Gene ID: 1833) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005069A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005069B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPYC\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPYC\u003c\/strong\u003e gene (Gene ID: 1833) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPYC\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPYC\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPYC\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPYC\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPYC\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPYC in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPYC siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPYC expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005069A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPYC siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPYC siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPYC siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005069B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPYC siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPYC siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPYC siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPYC siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/1833\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165429162349,"sku":"SI005069A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165511508333,"sku":"SI005069B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_2e193f15-1339-41be-9a01-bc308cb4d7db.png?v=1774683684"},{"product_id":"human-ep400-pre-designed-sirna-bhn20105014","title":"Human EP400 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEP400\u003c\/strong\u003e gene (NCBI Gene ID: 57634) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005014A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005014B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEP400\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEP400\u003c\/strong\u003e gene (Gene ID: 57634) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEP400\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEP400\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEP400\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEP400\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEP400\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EP400 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EP400 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EP400 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005014A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EP400 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EP400 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EP400 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005014B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EP400 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EP400 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EP400 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EP400 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/57634\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165429195117,"sku":"SI005014A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165510066541,"sku":"SI005014B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_c22ff222-b4af-42d0-85ea-b2a8fd249ffa.png?v=1774683687"},{"product_id":"human-espn-pre-designed-sirna-bhn20105144","title":"Human ESPN Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eESPN\u003c\/strong\u003e gene (NCBI Gene ID: 83715) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005144A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005144B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eESPN\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eESPN\u003c\/strong\u003e gene (Gene ID: 83715) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eESPN\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eESPN\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eESPN\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eESPN\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eESPN\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of ESPN in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent ESPN siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline ESPN expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005144A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ESPN siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ESPN siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ESPN siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005144B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ESPN siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ESPN siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ESPN siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ESPN siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/83715\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165429260653,"sku":"SI005144A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165513965933,"sku":"SI005144B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_223ec5ce-4fc0-4c6e-b2ce-4d2da1de7127.png?v=1774683680"},{"product_id":"human-eppin-wfdc6-pre-designed-sirna-bhn20105058","title":"Human EPPIN-WFDC6 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eEPPIN-WFDC6\u003c\/strong\u003e gene (NCBI Gene ID: 100526773) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005058A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005058B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eEPPIN-WFDC6\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eEPPIN-WFDC6\u003c\/strong\u003e gene (Gene ID: 100526773) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eEPPIN-WFDC6\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eEPPIN-WFDC6\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eEPPIN-WFDC6\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eEPPIN-WFDC6\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eEPPIN-WFDC6\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of EPPIN-WFDC6 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent EPPIN-WFDC6 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline EPPIN-WFDC6 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005058A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPPIN-WFDC6 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPPIN-WFDC6 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPPIN-WFDC6 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005058B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman EPPIN-WFDC6 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPPIN-WFDC6 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPPIN-WFDC6 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman EPPIN-WFDC6 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/100526773\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165429227885,"sku":"SI005058A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165511082349,"sku":"SI005058B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_7414936b-b638-4dfe-a843-5bd483de32e0.png?v=1774683677"}],"url":"https:\/\/www.ebiohippo.com\/collections\/sirna.oembed","provider":"BioHippo","version":"1.0","type":"link"}